Platelet reactivity and pharmacodynamic response to ticagrelor in patients undergoing extracorporeal cardiopulmonary resuscitation compared with conventionally resuscitated cardiac arrest patients
This study demonstrates that patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) exhibit delayed and attenuated platelet inhibition in response to enteral ticagrelor compared to conventionally resuscitated cardiac arrest patients, despite a concurrent trend toward increased bleeding risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When the heart stops, the body enters a race against time. In the most critical cases, doctors may use a machine called extracorporeal membrane oxygenation, or ECMO, to take over the work of the heart and lungs. This life-support system pumps blood outside the body, oxygenates it, and returns it, keeping the patient alive while the heart recovers. However, this artificial circuit creates a complex chemical environment inside the body. The blood coming into contact with the plastic tubes of the machine triggers a chain reaction that can make platelets—the tiny cell fragments responsible for clotting—either overactive or exhausted. To prevent dangerous clots from forming inside the machine or on stents placed in the heart, patients are given powerful blood-thinning medications. One such drug is ticagrelor, which works by blocking a specific signal that tells platelets to clump together. The challenge for doctors is finding the right balance: giving enough medication to stop a clot from forming, but not so much that the patient bleeds uncontrollably.
This delicate balance becomes even harder to manage when a patient is in cardiac arrest and requires ECMO support. In these situations, the body is under immense stress, and the usual rules of how drugs work may not apply. A new study from the University Medical Centre Ljubljana in Slovenia set out to understand exactly how the body responds to ticagrelor in patients receiving this advanced life support. The researchers compared two groups of adults who had suffered cardiac arrest and needed a procedure to open blocked heart arteries. One group received the standard treatment of resuscitation and medication, while the other group required the ECMO machine to survive. Both groups received the same dose of crushed ticagrelor, which was fed through a tube into the stomach, a common method for patients who cannot swallow.
The scientists measured how well the drug was working by testing the blood at various intervals after the medication was given. They used two different laboratory tests to see how easily the platelets would stick together. One test, known as VerifyNow, looks specifically at the pathway the drug is meant to block. The other test, called Multiplate, measures the overall ability of platelets to clump in a sample of whole blood. The results revealed a surprising difference between the two groups. In the patients who did not need the ECMO machine, the drug worked quickly, and the platelet activity dropped to a safe level within a few hours. In the patients supported by the ECMO machine, the drug took much longer to work, and its effect was significantly weaker.
Even though the patients on ECMO started with lower platelet counts, which usually suggests a higher risk of bleeding, the drug failed to suppress their platelet activity as effectively as it did in the other group. For the first four hours after receiving the medication, the platelet activity in the ECMO patients remained high, staying above the threshold where doctors consider the treatment to be effective. On average, the measure of platelet activity in these patients was 95 units higher than in the patients who did not have the machine. This suggests that the crushed pill was not being absorbed or processed correctly in the bodies of patients on life support. The researchers noted that the Multiplate test, which measures general clumping, did not show this difference, likely because the low number of platelets in the ECMO patients masked the problem. The VerifyNow test, which focuses on the specific drug target, provided a clearer picture of the drug's failure to work as intended.
The study also looked at safety, specifically the risk of bleeding. The patients on ECMO showed a trend toward more frequent major bleeding events compared to the other group, with 43.8 percent experiencing significant bleeding versus 15.0 percent in the control group. This creates a difficult situation for medical teams: the patients are at high risk of forming clots because the drug is not working fast enough, yet they are also at high risk of bleeding because of the machine and the stress of the event. The researchers concluded that the standard approach of giving a crushed pill through a tube may not be reliable for these critically ill patients. They suggest that in the future, doctors might need to consider different types of medication, such as drugs given directly into the vein that work immediately and can be stopped quickly if bleeding occurs. This study highlights that the complex environment created by life-support machines changes how the body handles essential medications, requiring new strategies to keep patients safe.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.